Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes | Zendy

Gerasimos Filippatos | Zendy; Javed Butler | Zendy; Dimitrios Farmakis | Zendy; Faı̈ez Zannad | Zendy; Anne Pernille Ofstad | Zendy; João Pedro Ferreira | Zendy; Jennifer B. Green | Zendy; Julio Rosenstock | Zendy; Sven Schnaidt | Zendy; Martina Brueckmann | Zendy; Stuart J. Pocock | Zendy; Milton Packer | Zendy; Stefan D. Anker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

Author(s) -

Gerasimos Filippatos,

Javed Butler,

Dimitrios Farmakis,

Faı̈ez Zannad,

Anne Pernille Ofstad,

João Pedro Ferreira,

Jennifer B. Green,

Julio Rosenstock,

Sven Schnaidt,

Martina Brueckmann,

Stuart J. Pocock,

Milton Packer,

Stefan D. Anker

Publication year - 2022

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.122.059785

Subject(s) - empagliflozin , medicine , diabetes mellitus , ejection fraction , heart failure , cardiology , hazard ratio , prediabetes , placebo , type 2 diabetes , endocrinology , confidence interval , alternative medicine , pathology

Empagliflozin improves outcomes in patients with heart failure with a preserved ejection fraction, but whether the effects are consistent in patients with and without diabetes remains to be elucidated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research